Drug
Edp 978
Edp 978: highest development phase Phase 1, developed by Enanta Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Enanta Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| EDP-978 NCT07540910 | Phase 1 | Chronic Inducible Urticaria |
Latest
No recent events.
Follow Edp 978 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.